Aim: The cause of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection is multifactorial: hypersplenism, decreased thrombopoietin levels, and myelosuppression induced by HCV. Platelet counts increase after eradication of HCV; however, this mechanism is not fully understood. Therefore, the aim of this study was to determine the influence of these three factors on platelet counts.
Methods: We retrospectively analyzed data from 109 HCV-infected patients with platelet counts ≤150 × 10 /μL who achieved viral eradication using interferon-free anti-HCV therapy. Changes in hematological parameters, thrombopoietin levels, HCV titers, and spleen volumes, and the correlations among them were evaluated.
Results: HCV RNA levels significantly decreased at 4 weeks after initiating antiviral therapy. Platelet counts rapidly increased at 4 weeks from baseline (120 ± 35 vs. 106 ± 28 × 10 /μL, P < 0.001), and remained at a plateau until 48 weeks after initiating antiviral therapy. Neutrophil counts showed the same pattern. Spleen volume was evaluated in 32 patients and, among them, it decreased in 21 patients, but remained unchanged in seven and increased in four. In addition to patients with decreased spleen volume, patients with unchanged spleen volume showed marginally increased platelet counts. Thrombopoietin levels did not correlate with platelet counts.
Conclusions: Platelet counts increased at 4 weeks after starting anti-HCV treatment. Our results suggest that this rapid change was possibly caused by improvement of hypersplenism and HCV-induced myelosuppression resulting from anti-HCV therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hepr.13426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying key blood markers for bacteremia in elderly patients: insights into bacterial pathogens.
Front Cell Infect Microbiol
January 2025
Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, Fuding, Fujian, China.
Background: This study aimed to assess the distribution of bacteremia pathogens in elderly patients, examine the impact of gender on pathogen distribution, and evaluate the predictive value of routine blood parameters for diagnosing bacteremia.
Methods: A retrospective analysis was conducted on 151 elderly patients (≥60 years old) admitted to Fuding Hospital, Fujian University of Traditional Chinese Medicine between October 2022 and June 2023. Comprehensive routine blood tests and blood cultures were performed.
Hidden blood loss and risk factors after percutaneous endoscopic transforaminal lumbar interbody fusion.
Front Surg
January 2025
Research Institute of Orthopedics, The Affiliated Jiangnan Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Purpose: In this study, we aimed to assess the occurrence of hidden blood loss (HBL) and its associated risk factors in patients with lumbar degenerative diseases who underwent percutaneous endoscopic transforaminal lumbar interbody fusion (Endo-TLIF).
Methods: Sex, age, height, weight, body mass index, and medical history including hypertension, diabetes, and osteoporosis were recorded. The duration of symptoms, preoperative lumbar subcutaneous fat tissue thickness (measured using midsagittal T2-weighted magnetic resonance imaging), lumbar disc degeneration grade, and other basic patient information were also documented.
Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report.
Exp Ther Med
March 2025
Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R. China.
Chronic myeloid leukemia with extreme thrombocytosis (CML-T), defined by a platelet count >1,000x10/l is a rare leukemia subtype. The present case report described a 66-year-old female CML-T patient presenting with a platelet count of 3,798x10/l, but a consistently normal spleen size. Following treatment with imatinib combined with interferon-α, the patient achieved hematological remission within 2 months, with a platelet count reduction to 311x10/l and complete cytogenetic remission after 10 months.
View Article and Find Full Text PDFRisk factors and machine learning prediction models for intrahepatic cholestasis of pregnancy.
BMC Pregnancy Childbirth
January 2025
Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang, 314001, China.
Background: Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs in the second and third trimesters of pregnancy and is associated with a significant risk of fetal complications, including premature birth and fetal death. In clinical practice, the diagnosis of ICP is predominantly based on the presence of pruritus in pregnant women and elevated serum total bile acid. However, this approach may result in missed or delayed diagnoses.
View Article and Find Full Text PDFCoagulation abnormalities following brown recluse spider (Loxosceles reclusa) envenomation: A description of 2 cases and review of the literature.
Am J Clin Pathol
January 2025
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, US.
Objective: Hemostatic abnormalities, including disseminated intravascular coagulation (DIC), are often cited as a common finding in patients following Loxosceles spider envenomation (ie, loxoscelism). The prevalence and severity of coagulopathy, however, particularly following L reclusa (ie, brown recluse) envenomation, is not well described. This study aimed to characterize coagulation laboratory parameters and coagulopathy in patients following L reclusa envenomation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!